This book aims to present a comprehensive, clinically relevant, and research driven exploration of radioligand therapy. It traverses the historical evolution of radiopharmaceuticals, molecular principles of targeted therapy, clinical applications across various malignancies, and emerging future directions, including personalized dosimetry and artificial intelligence integration. Special attention is given to patient perspectives, global access challenges, regulatory landscapes, and healthcare economics.